Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.66 - $2.62 $344,561 - $543,825
-207,567 Reduced 72.83%
77,433 $128,000
Q1 2024

May 15, 2024

BUY
$1.78 - $2.53 $507,300 - $721,050
285,000 New
285,000 $518,000

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $9.99M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Corsair Capital Management, L.P. Portfolio

Follow Corsair Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corsair Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Corsair Capital Management, L.P. with notifications on news.